166 related articles for article (PubMed ID: 8318413)
1. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.
Steyerberg EW; Keizer HJ; Zwartendijk J; Van Rijk GL; Van Groeningen CJ; Habbema JD; Stoter G
Br J Cancer; 1993 Jul; 68(1):195-200. PubMed ID: 8318413
[TBL] [Abstract][Full Text] [Related]
2. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer.
Fosså SD; Aass N; Ous S; Høie J; Stenwig AE; Lien HH; Paus E; Kaalhus O
J Urol; 1989 Nov; 142(5):1239-42. PubMed ID: 2478726
[TBL] [Abstract][Full Text] [Related]
3. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
4. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
[TBL] [Abstract][Full Text] [Related]
5. The changing role of surgery in metastatic non-seminomatous germ cell tumour.
Cassidy J; Lewis CR; Kaye SB; Kirk D
Br J Cancer; 1992 Jan; 65(1):127-9. PubMed ID: 1370759
[TBL] [Abstract][Full Text] [Related]
6. Failure of salvage treatment in metastatic testicular teratoma.
Whillis D; Coleman RE; Cornbleet MA; Howard GC
Clin Oncol (R Coll Radiol); 1991 May; 3(3):141-6. PubMed ID: 1712626
[TBL] [Abstract][Full Text] [Related]
7. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy.
Gelderman WA; Schraffordt Koops H; Sleijfer DT; Oosterhuis JW; Van der Heide JN; Mulder NH; Marrink J; De Bruyn HW; Oldhoff J
J Surg Oncol; 1988 Aug; 38(4):227-32. PubMed ID: 2457771
[TBL] [Abstract][Full Text] [Related]
8. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.
Steyerberg EW; Gerl A; Fossá SD; Sleijfer DT; de Wit R; Kirkels WJ; Schmeller N; Clemm C; Habbema JD; Keizer HJ
J Clin Oncol; 1998 Jan; 16(1):269-74. PubMed ID: 9440752
[TBL] [Abstract][Full Text] [Related]
9. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections.
Steyerberg EW; Keizer HJ; Stoter G; Habbema JD
Eur J Cancer; 1994; 30A(9):1231-9. PubMed ID: 7999405
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
[TBL] [Abstract][Full Text] [Related]
11. Prognosis in patients with metastatic non-seminomatous testicular cancer.
Aass N; Fosså SD; Ous S; Stenwig AE; Lien HH; Paus E; Kaalhus O
Radiother Oncol; 1990 Apr; 17(4):285-92. PubMed ID: 1693003
[TBL] [Abstract][Full Text] [Related]
12. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
Calaminus G; Schneider DT; Weissbach L; Schönberger S; Okpanyi V; Leuschner I; Poremba C; Göbel U
Klin Padiatr; 2009; 221(3):136-40. PubMed ID: 19437360
[TBL] [Abstract][Full Text] [Related]
13. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
[TBL] [Abstract][Full Text] [Related]
14. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis.
Steyerberg EW; Marshall PB; Keizer HJ; Habbema JD
Cancer; 1999 Mar; 85(6):1331-41. PubMed ID: 10189139
[TBL] [Abstract][Full Text] [Related]
15. Surgery following chemotherapy for metastatic testicular teratoma.
Whillis D; Coleman RE; Lessells AM; Hargreave TB; Cornbleet MA; Howard GC
Br J Urol; 1991 Sep; 68(3):292-5. PubMed ID: 1913071
[TBL] [Abstract][Full Text] [Related]
16. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?
Herr HW
Br J Urol; 1997 Oct; 80(4):653-7. PubMed ID: 9352708
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
18. Predictors of residual mass requiring surgical resection after chemotherapy of stage III testicular cancer. A prospective study.
Javadpour N; Young JD
Urology; 1992 Jul; 40(1):7-8. PubMed ID: 1320303
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of testicular cancer: 10-year experience.
Ondrus D; Hornák M; Matoska J; Kausitz J; Belan V; Cársky S
Neoplasma; 1993; 40(4):247-53. PubMed ID: 7505886
[TBL] [Abstract][Full Text] [Related]
20. Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors.
Ganjoo KN; Rieger KM; Kesler KA; Sharma M; Heilman DK; Einhorn LH
Cancer; 2000 Mar; 88(5):1051-6. PubMed ID: 10699894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
